Royalty Pharma Strengthens Executive Leadership Team to Support Strategic Growth and Investment Expansion
Royalty Pharma plc has announced a significant expansion of its senior leadership team, underscoring the company’s continued growth ambitions and its commitment to strengthening its position as a global leader in the biopharmaceutical royalty market. The company revealed that Greg Butz will join as Executive Vice President, Partnering & Investments, with his appointment set to take effect in June 2026. This strategic hire is expected to enhance Royalty Pharma’s capabilities in deal origination, strategic partnerships, and complex investment execution across the global healthcare landscape.
Greg Butz brings with him more than two decades of experience in healthcare investment banking, having most recently served as Global Co-Head of Healthcare Investment Banking at Bank of America. His deep expertise in advising biopharmaceutical companies on capital raising, mergers and acquisitions, and long-term strategic planning positions him as a valuable addition to Royalty Pharma’s executive leadership team. His appointment reflects the company’s proactive approach to scaling its investment platform in response to increasing demand for innovative funding solutions within the life sciences sector.
Commenting on the appointment, Pablo Legorreta, Chief Executive Officer and Chairman of Royalty Pharma, expressed strong enthusiasm about Butz joining the organization. He emphasized that Butz’s extensive experience and proven track record in the healthcare investment banking space would significantly strengthen the company’s leadership bench. Legorreta highlighted that as Royalty Pharma continues to expand its market opportunity and experiences a surge in transaction activity, bringing in a leader of Butz’s caliber is both timely and strategically important.
Legorreta also pointed to the broader expansion of the company’s leadership team, noting the recent appointment of Ken Sun as Head of Asia. This move reflects Royalty Pharma’s increasing focus on global markets, particularly in regions with rapidly growing biopharmaceutical innovation ecosystems. According to Legorreta, the combined expertise of Butz, Sun, and Chris Hite will create a highly complementary leadership structure capable of driving the company’s global growth strategy and enhancing its ability to originate and execute differentiated royalty transactions worldwide.
As part of this leadership transition, Chris Hite has been appointed Chairman, Partnering & Investments. In this newly defined role, Hite will continue to play a pivotal part in shaping Royalty Pharma’s strategic direction, particularly by expanding its global relationship network and contributing to high-impact transactions. Hite has been instrumental in the company’s evolution over the years, helping to establish Royalty Pharma as a leading player in the royalty financing space. His deep industry relationships and strategic insight are expected to remain central to the company’s ongoing success.
Legorreta acknowledged Hite’s contributions, describing him as a highly valued partner whose leadership and dedication have been critical to both the growth of Royalty Pharma and the broader development of the royalty market. The transition to Chairman, Partnering & Investments allows Hite to focus on leveraging his extensive network and experience while continuing to provide strategic guidance at the highest level.
Hite himself expressed strong support for the appointment of Greg Butz, noting that his extensive experience and established relationships across the biopharmaceutical ecosystem make him an ideal addition to the team. Hite emphasized that he looks forward to collaborating closely with Butz to further strengthen Royalty Pharma’s global platform and capitalize on the significant opportunities ahead. This collaborative approach reflects the company’s culture of leveraging collective expertise to drive innovation and growth.
In his remarks, Greg Butz conveyed his excitement about joining Royalty Pharma at what he described as a particularly dynamic and promising time for the company. He highlighted Royalty Pharma’s role in establishing royalties as a core component of the capital structure for many high-quality biopharmaceutical companies. This model has gained increasing traction as companies seek alternative funding mechanisms that allow them to access capital without diluting equity or taking on excessive debt.
Butz noted that he is eager to contribute to the development of creative, mutually beneficial funding solutions that support the goals of Royalty Pharma’s partners. His experience in structuring complex financial transactions and advising companies across various stages of growth is expected to play a key role in advancing the company’s mission. By facilitating innovative partnerships, Butz aims to help biopharmaceutical companies unlock value from their assets while accelerating the development and commercialization of new therapies.
The appointment of Greg Butz comes at a time when the biopharmaceutical industry is experiencing rapid innovation and increasing demand for flexible financing solutions. The royalty model, which involves providing upfront capital in exchange for a share of future product revenues, has emerged as an attractive option for companies looking to fund research and development, expand their pipelines, or pursue strategic acquisitions. Royalty Pharma has been at the forefront of this trend, building a diversified portfolio of royalty interests across a wide range of therapeutic areas.
By strengthening its leadership team, Royalty Pharma is positioning itself to capture a larger share of this growing market. The addition of a seasoned investment banker like Butz enhances the company’s ability to identify and execute high-quality transactions, particularly in an increasingly competitive environment. His global perspective and deep industry connections are expected to open new avenues for collaboration and investment.
Greg Butz’s professional background further underscores the strategic value he brings to Royalty Pharma. During his tenure at Bank of America, he worked extensively with both public and private biopharmaceutical companies, advising them on a broad spectrum of financial and strategic initiatives. His experience spans capital raising transactions, including equity and debt offerings, as well as mergers, acquisitions, and other strategic partnerships. This breadth of experience provides him with a comprehensive understanding of the financial needs and challenges faced by companies in the life sciences sector.
Prior to serving as Global Co-Head of Healthcare Investment Banking, Butz held several senior leadership roles within Bank of America, including Co-Head of North American Healthcare Investment Banking and Head of Life Sciences Investment Banking. In these positions, he played a key role in building and leading high-performing teams, developing client relationships, and executing complex transactions. His leadership experience is expected to translate well into his new role at Royalty Pharma, where collaboration and strategic execution are critical to success.
In terms of academic credentials, Butz holds a Bachelor of Arts degree from Williams College and a Master of Business Administration from Dartmouth. His educational background, combined with his extensive professional experience, provides a strong foundation for his role at Royalty Pharma.
The expansion of Royalty Pharma’s leadership team reflects a broader trend within the biopharmaceutical industry, where companies are increasingly investing in talent and capabilities to navigate a rapidly evolving landscape. As scientific advancements continue to drive innovation, the need for sophisticated financial solutions is becoming more pronounced. Companies like Royalty Pharma play a crucial role in bridging the gap between innovation and commercialization by providing the capital necessary to bring new therapies to market.
Looking ahead, Royalty Pharma’s enhanced leadership structure is expected to support its strategic priorities, including expanding its global footprint, deepening its relationships with biopharmaceutical partners, and continuing to innovate within the royalty financing model. The combined expertise of its leadership team positions the company well to capitalize on emerging opportunities and deliver long-term value to its stakeholders.
In conclusion, the appointment of Greg Butz as Executive Vice President, Partnering & Investments marks a significant milestone for Royalty Pharma. Alongside the leadership contributions of Pablo Legorreta, Chris Hite, and Ken Sun, Butz’s addition reinforces the company’s commitment to excellence, innovation, and growth. As the biopharmaceutical industry continues to evolve, Royalty Pharma’s strengthened leadership team is poised to play a central role in shaping the future of royalty-based financing and supporting the development of life-changing therapies worldwide.
About Royalty Pharma
Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies.
Royalty Pharma’s current portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta and Alyftrek, GSK’s Trelegy, Biogen’s Tysabri and Spinraza, Roche’s Evrysdi, Astellas and Pfizer’s Xtandi, Johnson & Johnson’s Tremfya, AbbVie and Johnson & Johnson’s Imbruvica, Servier’s Voranigo, Gilead’s Trodelvy, Amgen’s Imdelltra and Alnylam’s Amvuttra, among others, and 19 development-stage product candidates.
Source Link: https://www.royaltypharma.com/
